Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Correlates of immunity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Correlates of immunity. Displaying page 1 of 1.
    EudraCT Number: 2015-003250-41 Sponsor Protocol Number: 1 Start Date*: 2015-09-15
    Sponsor Name:Public Health England
    Full Title: Protection induced by Live Attenuated Influenza Vaccine (LAIV or Fluenz Tetra) - applied epidemiological study
    Medical condition: There is no medical condition associated with this trial. The trial involves vaccination of healthy children with a licensed product according to the SmPC. The vaccination is Fluenz Tetra, a live...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002358-31 Sponsor Protocol Number: LTR138 Start Date*: 2006-09-11
    Sponsor Name:RIVM
    Full Title: Specific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults
    Medical condition: Bacterial meningitis is caused by several pathogens such as Hib, Streptococcus pneumoniae and MenC. A MenC conjugate vaccination was introduced into the National Vaccination Program at the age of 1...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006804-46 Sponsor Protocol Number: MAL034 Start Date*: 2009-02-26
    Sponsor Name:University of Oxford
    Full Title: Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAP
    Medical condition: Malaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006495-16 Sponsor Protocol Number: PrEPSo Start Date*: 2022-02-25
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders
    Medical condition: Covid 19 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002697-80 Sponsor Protocol Number: MADI-02 Start Date*: Information not available in EudraCT
    Sponsor Name:Université Libre de Bruxelles
    Full Title: Maternal determinants of infant immunity to pertussis
    Medical condition: Vaccination against whooping cough in non-pregnant women and in pregnant women. Vaccination against whooping cough in the Belgian vaccination program in children from 2 months of age
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007182-23 Sponsor Protocol Number: MenOccy/I72P1 Start Date*: 2010-03-16
    Sponsor Name:Health Protection Agency
    Full Title: A phase 2, open-label study of the safety, tolerability and immunogenicity of a Novartis meningococcal B vaccine when administered at a 0, 2, 6 month schedule and of a single dose of Novartis menin...
    Medical condition: The study investigates the ability of the two vaccines to induce protective immunity against meningococcal disease.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004360-44 Sponsor Protocol Number: VAC034 Start Date*: 2008-04-29
    Sponsor Name:University of Oxford
    Full Title: Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAP
    Medical condition: Malaria
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003842-18 Sponsor Protocol Number: OTL-103-4 Start Date*: 2019-01-08
    Sponsor Name:Orchard Therapeutics Ltd.
    Full Title: A Single Arm, Open Label Clinical Study of Haematopoietic Stem Cell Gene Therapy with Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector encoding WAS cDNA in Subjects with Wisko...
    Medical condition: Wiskott-Aldrich Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10061598 Immunodeficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000673-68 Sponsor Protocol Number: 16IC17 Start Date*: 2018-10-09
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Phase I/II study of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan
    Medical condition: Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069566 Severe combined immunodeficiency syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:25:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA